Modified factor viii

Abstract

Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.

1 . A method for treating a patient having factor VIII deficiency comprising administering a therapeutically effective amount of a modified porcine factor VIII protein having the amino acid sequence of amino acids 1 to 1448 of SEQ ID NO:49. 
     
     
         2 . The method according to  claim 1 , wherein the patient having factor VIII deficiency has inhibitory antibodies to human factor VIII. 
     
     
         3 . The method according to  claim 1 , wherein the patient having factor VIII deficiency suffers from uncontrolled bleeding. 
     
     
         4 . The method according to  claim 3 , wherein the uncontrolled bleeding is selected from intra-articular, intracranial, and gastrointestinal hemorrhage. 
     
     
         5 . The method according to  claim 1 , wherein the modified porcine factor VIII protein is an expression product of DNA according to SEQ ID NO:48, expressed in a mammalian host cell. 
     
     
         6 . The method according to  claim 5 , wherein the modified porcine factor VIII is prepared from the supernatant of cultured mammalian host cells containing and expressing DNA of SEQ ID NO:48. 
     
     
         7 . The method according to  claim 1  or  5  or  6 , wherein the modified porcine factor VIII protein consists of the sequence of amino acids between positions 1 and 1448 of SEQ ID NO:49. 
     
     
         8 . The method according to  claim 1 , wherein the modified porcine factor VIII further comprises a physiologically acceptable carrier. 
     
     
         9 . The method according to  claim 8 , wherein the modified porcine factor VIII further comprises a stabilizer and a delivery vehicle. 
     
     
         10 . The method according to  claim 1 , where in the modified porcine factor VIII is infused intravenously. 
     
     
         11 . The method according to  claim 1 , wherein the patient is an acquired hemophilia patient. 
     
     
         12 . The method according to  claim 1 , wherein the patient is a congenital hemophilia patient.